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Deregulation of miRNAs in 
malignant pleural mesothelioma 
is associated with prognosis and 
suggests an alteration of cell 
metabolism
Chiara De Santi1, Ombretta Melaiu2, Alessandra Bonotti3, Luciano Cascione4, Gianpiero Di 
Leva5, Rudy Foddis6, Alfonso Cristaudo6, Marco Lucchi7, Marco Mora8, Anna Truini8, Andrea 
Tironi9, Bruno Murer10, Renzo Boldorini11, Monica Cipollini12, Federica Gemignani12, Pierluigi 
Gasparini13, Luciano Mutti5 & Stefano Landi12
Malignant pleural mesothelioma (MPM) is an aggressive human cancer and miRNAs can play a key role 
for this disease. In order to broaden the knowledge in this field, the miRNA expression was investigated 
in a large series of MPM to discover new pathways helpful in diagnosis, prognosis and therapy. We 
employed nanoString nCounter system for miRNA profiling on 105 MPM samples and 10 healthy pleura. 
The analysis was followed by the validation of the most significantly deregulated miRNAs by RT-qPCR 
in an independent sample set. We identified 63 miRNAs deregulated in a statistically significant way. 
MiR-185, miR-197, and miR-299 were confirmed differentially expressed, after validation study. In 
addition, the results of the microarray analysis corroborated previous findings concerning miR-15b-5p, 
miR-126-3p, and miR-145-5p. Kaplan-Meier curves were used to explore the association between 
miRNA expression and overall survival (OS) and identified a 2-miRNA prognostic signature (Let-7c-5p 
and miR-151a-5p) related to hypoxia and energy metabolism respectively. In silico analyses with 
DIANA-microT-CDS highlighted 5 putative targets in common between two miRNAs. With the present 
work we showed that the pattern of miRNAs expression is highly deregulated in MPM and that a 
2-miRNA signature can be a new useful tool for prognosis in MPM.
MicroRNAs (miRNAs) are highly conserved small non-coding RNA molecules, 20–25 nucleotides long, which 
play an important regulatory role at post-transcriptional level. Each miRNA has multiple targets, thus slight 
variations in their expression could affect the behavior of a large variety of genes. Their abnormal expression has 
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been linked to multiple human diseases, including cancer1. MiRNAs can function as either tumour suppressors 
or oncogenes and this feature, together with their tissue-specific expression, has prompted the study of miRNAs 
expression levels as a possible important diagnostic and prognostic tool for several malignancies2. Moreover, 
miRNAs-driven genes/pathways deregulation gives countless potentially druggable targets for the development 
of innovative cures3.
In recent years a number of studies have profiled the miRNA content of Malignant Pleural Mesothelioma 
(MPM) cell lines and/or tumour tissues4. MPM is a lethal cancer with increasing worldwide incidence, often 
induced by asbestos exposure. To date, a few studies have evaluated the differential expression of miRNAs 
using different sample sources in the hope of improving MPM management. Recently, Truini et al. reviewed 
a wide range of publications regarding MPM miRNA expression data4 highlighting the heterogeneity of the 
results (sometimes contradictory) especially due to ‘technical factors’ such as: diversity of the histological sub-
types examined, different sample sources, diversity of the control groups, statistical approaches and different 
high-throughput platform used. From the published literature it seems established that miRNAs deregulated in 
MPM target genes fundamental for the development and progression of the disease, such as CDKN2A, NF2, JUN, 
HGF, and PDGFA4. As a matter of fact, most of these miRNAs mapped to chromosomal regions known to be 
altered in MPM, such as gain of 8q24 and deletion of 1p36, and 14q32.
To overcome some conflicting results, larger samples’ cohorts should be profiled and analysed to minimize 
false-positive findings. In order to broaden the knowledge on the miRNAs expression status in MPM, we profiled 
a large number of histologically confirmed FFPE MPM samples, using NanoString nCounter, a high throughput 
platform particularly suitable for miRNA profiling of FFPE samples. Validation of the most significantly dereg-
ulated miRNAs was done by the gold standard quantitative RT-qPCR on an independent group of MPM and 
controls tissues. Furthermore, using in silico approaches, we sought to better understand how the biology of MPM 
might be differentially impacted by the expression patterns of key miRNAs. Finally, miRNA expression was cor-
related to patient overall survival (OS). As a result, we built a 2-miRNA signature able to divide MPM patients in 
high and low risk that has allowed us to highlight the role of microenvironment and energy metabolism in MPM.
Results
Several miRNAs are deregulated in MPM. We used a microarray approach to analyse miRNAs profile 
of a series of 96 MPM patients compared to 10 normal pleura samples. Raw and normalised expression data 
are provided individually for each sample for each of the 800 miRNAs detected by the nanoString platform in 
Supplementary Table 1.
Limma analysis identified a total of 63 deregulated miRNAs represented in Fig. 1. Among them, 55 were 
down-regulated and 8 were up-regulated in MPM samples (detailed information are available in Supplementary 
Table 2). The expression levels of miRNAs were ranked according to BH values and the top five significant miR-
NAs were: miR-337-3p, miR-185-5p, miR-485-3p, miR-197-3p, and miR-299-5p, all down-regulated in MPM. 
These were selected for validation with RT-qPCR in an independent cohort of 16 MPM and 17 control tissues. 
The extent of differential expression was quantified by calculating the log2(fold change) (i.e., log2(FC)) using the 
Figure 1. Heat map representing hierarchical clustering of 63 statistically significantly deregulated miRNAs 
detected in the present work on 96 MPM and 10 control tissues. Rows: miRNAs; columns: samples; red: high 
expression; blue: low expression.
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normal pleural specimens as control samples. We observed a statistically significant down-regulation in MPM 
samples, after Bonferroni’s correction, for miR-197, miR-185 and miR-299 (see Table 1), whereas we could not 
validate the results for miR-337 and miR-485. Raw and normalised Ct (Threshold Cycle) values for each sample 
for each miRNA are provided in Supplementary Table 3.
In addition, from our microarray analysis we could confirm previous findings from several high-throughput 
studies where mesothelial cell lines or normal mesothelial tissues were used as controls (Table 2). Interestingly, 
we found a statistically significant down-regulation of miR-126-3p, miR-15b-5p, and miR-145-5p, which showed 
to have a functional role in MPM according to in vitro and in vivo studies5–7. The log2 (FC) was −0.307 for miR-
126 (p-value after BH correction = 0.014), −0.917 for miR-15b (0.00265), and −0.326 for miR-145 (0.014). Thus, 
overall, we confirmed the role played by miR-126, miR-15b and miR-145 and, in addition, we suggest a role for 
miR-185, miR-197, and miR-299 in MPM.
In silico analysis suggested targets and pathways affected by the deregulated miRNAs. The 
putative mRNAs targeted by the 6 mentioned miRNAs (i.e. miR-126, miR-15b, miR-145, miR-185, miR-197 and 
miR-299) were predicted with DIANA-microT-CDS in silico tool and the top 50 predicted targets according to 
miTG score are reported in Supplementary Table 4. Interestingly, the intersection of the 6 lists of putative targets 
(shown in the last sheet of Supplementary Table 4) highlighted 5 transcripts in common between two miRNAs 
(GOLGA1, GOLGB1, PTPN9, PSMD1, TNRC6A).
When miRNAs were analysed with miRPath tool, the union of predicted or experimentally validated targets 
showed an enrichment for pathways involved in cancer and signaling cascades such as Wnt or MAPK pathways. 
The top 5 pathways significantly enriched are reported in Table 3, together with the miRNAs and their target 
genes mapped in the pathway. On the other hand, the intersection of predicted or experimentally validated targets 
highlighted the presence of further transcripts targeted by two or more deregulated miRNAs: MPLZ1 (targeted 
microRNA Log2(FC) p-value
miR-197-3p −2.540 3.72 × 10−7
miR-185-5p −2.742 2.22 × 10−4
miR-299-5p −1.239 0.0014
miR-337-3p −0.758 0.0201
miR-485-3p −0.488 0.1886
Table 1. Statistical analyses testing differences in expression levels (expressed as logarithm base 2 of the fold 
change) between MPM and controls in the validation series. In bold the three differentially expressed miRNAs 
are highlighted.
miRNA BH
Differential 
Expression
Direction of 
deregulation References
hsa-miR-152 2,66 × 10−12 −2,31 ↓ 20
hsa-miR-30c-5p 1,73 × 10−09 −2,40 ↓, ↑ 20, 22
hsa-miR-542-5p 3,66 × 10−08 −0,30 ↑ 20
hsa-miR-92a-3p 5,26 × 10−07 −2,61 ↑ 21
hsa-miR-423-3p 2,28 × 10−06 −1,85 ↓ 19
hsa-miR-214-3p 5,75 × 10−06 −4,23 ↓ 21
hsa-miR-29b-3p 1,49 × 10−05 3,15 ↓ 20
hsa-miR-10b-5p 0,000144 −2,84 ↓ 20
hsa-miR-146b-5p 0,000298 −2,77 ↓ 21
hsa-miR-127-3p 0,000302 −4,89 ↓ 20
hsa-miR-221-3p 0,000633 −2,69 ↓ 20
hsa-miR-15b-5p 0,00265 −2,79 ↓ 6
hsa-miR-195-5p 0,00322 −2,53 ↓ 6
hsa-miR-204-5p 0,00399 −1,65 ↓ 7
hsa-miR-145-5p 0,01436 −1,83 ↓ 7, 23
hsa-miR-126-3p 0,01436 −1,76 ↓ 22, 23
hsa-miR-451a 0,04051 −2,63 ↓ 23
hsa-miR-146a-5p 0,04636 −2,93 ↓ 20
Table 2. List of miRNAs deregulated according to the present nanostring analysis that were previously reported 
in relation to miRNA profiling data in MPM; BH = P-value of the comparison between MPM vs non-MPM 
after Benjamini-Hochberg correction for multiple test; the trend of the deregulation according to our analysis is 
expressed as “Differential Expression”, the trend reported in literature is expressed as arrows (↑ = up-regulated, 
↓ = down-regulated).
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by miR-145, -185, and -197), PRKAR2A (miR-185, -15b and -299), CCNE1 (miR-15b and miR-185), and VEGFA 
(miR-126 and miR-15b).
A 2-miRNA signature has an independent prognostic value for MPM. Finally, miRNAs from 
microarray analysis were also evaluated as potential prognostic biomarkers, considering only the 52 MPM 
patients for whom the survival data were available. We identified a 2-miRNA signature based on Let-7c-5p and 
miR-151a-5p expression levels. The OS and a risk score for each patient was calculated as explained in the mate-
rials and methods section. The OS rates were significantly lower in the patient group with the high-risk score 
(P = 0.004 by the log-rank test; Fig. 2A). We next sought to validate the risk score using the miRseq data from 
the TCGA (The Cancer Genome Atlas) mesothelioma dataset. When patients in validation cohort were strati-
fied according to their risk score, the group with a low risk score had a significantly better prognosis (P = 0.021 
for OS, log-rank test) than group with a high risk score (Fig. 2B). Similar results were obtained when assessing 
the 2-miRNA signature in association with prognosis in our cohort of 16 fresh frozen MPM (P = 0.038 for OS, 
log-rank test; Fig. 2C). Taken together, these results show that the classifier based on Let-7c-5p and miR-151a-5p 
expression levels has great potential as prognostic tool.
In order to ascertain whether the 2-microRNA signature indeed performs better than single miRNAs, we 
compared the performances of the 2-microRNA signature and the single miRNAs for OS by Akaike information 
criterion (AIC). The lowest AIC of the model is based on the two miRNAs taken together and it suggests its better 
performance than the single miRNAs in our cohort (307.1 vs 310.1 and 310.0) and in the TCGA cohort as well 
(402.3 vs 403.4 and 403).
The effect of risk score, gender, age and histotype on patient survival was further evaluated by multivariate Cox 
proportional hazard model on 52 MPM subjects from the microarray sample set. Histologic subtype and gender 
were not associated with survival in our sample set (P = 0.34 and P = 0.20, respectively), while a lower age at the 
diagnosis (<65 years old) was significantly associated with better prognosis (P = 0.001). In this model, risk score 
was an independent predictor of patient survival (P = 0.002).
TarBasemode
KEGG pathways
miRNAs mapped in the 
pathway MiRNA target genes mapped in the pathway
Adjusted 
P-value
Pathways in cancer
miR-15b-5p, miR-126-3p, 
miR-145-5p, miR-299-5p, 
miR-197-3p, miR-185-5p
E2F1, CRK, RAD51, PIK3R2, BCL2, IGF1R, RHOA, CDK6, 
TPM3, CCND1, CNE2, MMP1, AKT1, MYC, CDC42, 
CCNE1, CDKN1A, STAT1, VEGFA
5.71 × 10−13
Hepatitis B
miR-15b-5p, miR-126-3p, 
miR-145-5p, miR-299-5p, 
miR-197-3p, miR-185-5p
E2F1, ATF6B, PIK3R2, IFNB1, BCL2, CDK6, CCND1, 
CCNE2, AKT1, TIRAP, MYC, CCNE1, CDKN1A, STAT1 2.10 × 10
−11
Pancreatic cancer
miR-15b-5p, miR-126-3p, 
miR-145-5p, miR-197-3p, 
miR-185-5p
E2F1, RAD51, PIK3R2, CDK6, CCND1, AKT1, CDC42, 
STAT1, VEGFA 2.06 × 10
−09
Small cell lung cancer miR-15b-5p, miR-126-3p, miR-145-5p, miR-185-5p
E2F1, PIK3R2, BCL2, CDK6, CCND1, CCNE2, AKT1, MYC, 
CCNE1 9.77 × 10
−09
Non-small cell lung 
cancer
miR-15b-5p, miR-126-3p, 
miR-197-3p, miR-185-5p E2F1, PIK3R2, CDK6, CCND1, AKT1, FOXO3 7.40 × 10
−08
microT-CDS mode
Fatty acid biosynthesis miR-15b-5p, miR-185-5p FASN, OXSM, ACACB 5.48 × 10−23
MAPK signaling pathway
miR-15b-5p, miR-145-5p, 
miR-299-5p, miR-197-3p, 
miR-185-5p
CACNG8, PDGFRA, CACNA2D3, NFKB1, PTPRQ, GNA12, 
SOS2, CRK, MAPK7, PAK2, GCK, CACNB4, CACNG7, 
MAPK14, LAMTOR3, RAF1, MAP3K4, TAOK1, MAP2K6, 
IKBKB, FGF11, PPP3CA, NLK, DUSP10, RAPGEF2, 
NFATC2, MAPK8, PPM1A, FLNB, FLNA, CACNA1E, 
CACNG4, FGF2, CDC42, CACNA2D4, FGF18, HSPA8, NF1, 
PRKCB, RPS6KA3, AKT3, MAP2K1, MKNK1, MAP3K8, 
CACNA2D1, RPS6KA4, RELA, CACNA1D, FGFR1, FGF7, 
PLA2G4C, ARRB1
8.62 × 10−09
Wnt signaling pathway
miR-15b-5p, miR-145-5p, 
miR-299-5p, miR-197-3p, 
miR-185-5p
CTNNBIP1, CAMK2D, DAAM2, LRP6, WNT7A, BTRC, 
VANGL1, CCND2, SMAD3, WNT2B, PPP2R5C, WNT5B, 
SKP1, PPP2R5A, PPP3CA, NLK, PLCB1, FZD4, SENP2, 
FZD10, CCND1, AXIN2, NFATC2, MAPK8, PPP2R1A, 
SIAH1, PRKCB, CXXC4, WNT3A, WIF1, WNT9B, NFATC3, 
PPP2R1B, TBL1XR1, CCND3
1.06 × 10−08
p53 signaling pathway
miR-15b-5p, miR-145-5p, 
miR-299-5p, miR-197-3p, 
miR-185-5p
CCNG1, ZMAT3, BAI1, RFWD2, CDK2, CCND2, PERP, 
CDK6, CHEK1, CCND1, SHISA5, SESN1, SIAH1, CCNE1, 
IGFBP3, SESN3, PTEN, PPM1D, CCND3
2.88 × 10−08
Focal adhesion
miR-15b-5p, miR-126-3p, 
miR-145-5p, miR-299-5p, 
miR-197-3p, miR-185-5p
ACTB, PDGFRA, MYLK4, SOS2, CRK, PAK2, COL24A1, 
PPP1CC, CCND2, ITGB6, PAK7, RAF1, BCL2, IGF1R, 
ZYX, VCL, ITGA1, PTK2, CCND1, MAPK8, FLNB, FLNA, 
PIK3R1, COL4A4, CDC42, PAK6, PRKCB, AKT3, MYLK3, 
MAP2K1, ITGA6, VEGFA, PTEN, KDR, ARHGAP5, MYLK, 
CCND3, ILK
4.45 × 10−06
Table 3. The topfive deregulated pathways detected by miRPath (using either TarBase or microT-CDS mode), 
based on the target genes of the 6 miRNAs resulted deregulated in a statistically significant way.
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Moreover, the effect of risk score and therapy on the prognosis was evaluated on 27 MPM subjects for whom 
the information regarding the received treatments was available. A non-symptomatic therapy (including surgery, 
chemotherapy or radiotherapy) was significantly associated with a better prognosis (P = 0.008), and the risk score 
was again an independent factor of patient survival (P = 0.027).
Discussion
MPM is a very aggressive and heterogeneous tumour8. Its biology is still unclear and further studies are needed in 
order to discover new pathways potentially helpful in diagnosis, prognosis and therapy. MiRNAs were shown to 
play a key role in the pathogenesis of MPM4.
Here, we aimed to broaden the knowledge about miRNAs in MPM investigating the presence of differen-
tially expressed miRNAs using a microarray platform. This approach allowed the identification of six miRNAs 
(miR-15b, miR-126, miR-145, miR-185, miR-197, and miR-299), three of which (i.e. miR-185, miR-197 and miR-
299) have never been linked, to the best of our knowledge, to MPM carcinogenesis. These miRNAs have been 
shown to target specific pathways involved in cancer outcome, progression or therapy. For instance, miR-185 
Figure 2. Kaplan-Meyer curves representing the correlation between 2-miRNA signature based on Let-7c-5p 
and miR-151a-5p expression levels and overall survival rates in MPM patients. High levels (grey line) of Let-
7c-5p plus miR-151a-5p were associated with a significantly worse overall survival than low levels (black line) in 
patients recruited in the present study (A), in the TCGA mesothelioma dataset (B) and in an independent set of 
fresh frozen MPM (C) (P = 0.004, P = 0.021, and P = 0.038, respectively).
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was reported to be down-regulated in hepatocellular carcinoma and to inhibit tumour growth by targeting the 
DNMT1/PTEN/Akt pathway9, commonly activated in MPM10, 11. It was shown to suppress tumour prolifera-
tion in triple-negative breast cancer by directly targeting E2F6 and DNTM1 and by simultaneously upregulating 
BRCA112. A key anti-tumourigenic role of miR-185 was shown also in lung13 and gastric cancer14, modulating 
target mRNAs (i.e. AKT1 and TRIM29, respectively) involved in the carcinogenic process. Another study revealed 
a role of miR-197 as tumour suppressor in mediating apoptosis in multiple myeloma cells by targeting MCL115, 
while in non-small cell lung cancer it contributed, when down-regulated, to chemoresistance through the miR-
197/CKS1B/STAT3-mediated PD-L1 network16. MiR-299 was found down-regulated in prostatic cancer cell lines 
compared to normal cells17 and to play a role in autophagy inhibition by suppressing Atg5 in neurons18.
Moreover, we could replicate some of the results obtained by other authors6, 7, 19–23 who attempted to define 
a set of miRNAs differentially expressed between MPM and non-MPM mesothelial tissues (Table 2). Although 
we found 18 miRNAs already linked with MPM, the fact that some of the results were not in agreement with 
what previously reported should not be surprising. In fact, there are several reasons that could explain the only 
partial overlap with the literature data, i.e. different sample sources (FFPE vs fresh frozen tissues), different 
high-throughput platforms, different normalization techniques and, last but not least, the intrinsic heterogeneity 
of MPM. Nonetheless, we confirmed some interesting findings about three miRNAs (i.e. miR-15b, miR-126, 
and miR-145) that were shown to play a biological role in MPM. MiR-15b was down-regulated in MPM tumour 
specimens and was shown to inhibit growth of MPM cell lines6. It was also shown to act as tumour suppressor in 
liver cancer24 and its reduced expression was associated with chemo-resistance25 and poor prognosis26. MiR-126 
has been extensively studied in MPM, where it was shown to have a proper biological activity both in vitro and in 
vivo5 and a potential value as biomarker22, 23, 27. Many targets of miR-126 were experimentally validated in other 
cancer types, including VEGF-A28, ADAM929, Sox230, CRK, and PI3KR231. The involvement of miR-126 in the 
regulation of angiogenesis was shown also in hepatocellular carcinoma, where it acts as tumour suppressor by tar-
geting LRP6 and PIK3R232. MiR-145 loss was reported to have pro-tumourigenic effects in MPM, via modulating 
clonogenicity, cell migration, and resistance to pemetrexed7. It was shown to be downregulated and to function 
as a tumour suppressor in other malignancies, namely nasopharyngeal carcinoma33, non-small cell lung cancer34, 
and bladder cancer35.
Altogether, the “miRNomic” approach allows highlighting a list of deregulated miRNAs, which could act as 
tumour suppressor or oncogene according to their target mRNAs. This strategy partially overcomes the limitation 
of the transcriptomics, which gives information about the dysregulated transcripts, but does not provide reliable 
data regarding their protein products, since mRNA levels often do not correlate with protein contents36. Indeed, 
miRNAs target analysis could help in the identification of a pattern of proteins possibly deregulated. Thus, follow-
ing an in silico approach here we proposed novel targets for MPM, namely GOLGA1, GOLGB1, PTPN9, PSMD1, 
TNRC6A, MPLZ1, PRKAR2A, CCNE1 and VEGFA.
Once the protein targets will be validated as deregulated in MPM, novel therapeutic strategies could be 
undertaken using specific inhibitors. Following this concept, PSMD1 and VEGFA are among the most suitable 
candidate to be investigated. PSMD1 encodes one of the regulatory subunits of the proteasome complex and it 
was reported to be up-regulated in MPM37. It could suggest an unexplored therapeutic strategy for MPM, since 
the proteasome inhibitor Bortezomib has already shown to be effective in the treatment of multiple myeloma 
and mantle cell lymphoma38. VEGFA encodes the vascular endothelial growth factor A and it is reported to be 
up-regulated in mesothelioma39. The treatment with bevacizumab, a monoclonal antibody that blocks angiogen-
esis by inhibiting VEGF-A, in combination with pemetrexed plus cisplatin showed encouraging results in the 
therapy for MPM in a recent randomized phase III trial40.
A further aim of this study was to evaluate how miRNAs deregulation performs as a prognostic biomarker. 
Previous works highlighted the usefulness of miRNAs as prognostic biomarkers in MPM20, 23, 41, 42. While the ear-
lier studies suggested a prognostic value for single miRNAs (miR-29c*41, miR-17-5p and miR-30c-5p20), subse-
quent works attempted to increase the accuracy of the survival analysis using a combination of multiple miRNAs 
(four-miRNA classifier23 or six-miRNA score42). In line with this approach, we proposed here a 2-miRNA signa-
ture (Let-7c-5p plus miR-151a-5p) relating to overall survival, whose prognostic value was also validated in the 
TCGA mesothelioma dataset and in an independent set of fresh frozen MPM samples. Our study showed some 
discrepancies compared to the literature data, where general poor overlap among studies could be at least partially 
ascribed to different microarray platforms (for example, miR-29c* and miR-652-3p probes were not included in 
the Nanostring platform), to subtle different statistical analyses in the calculation of the survival curves and, as 
acknowledged before, to the intrinsic heterogeneity of MPM. Nonetheless, our results were consistent with data 
provided recently about an eight-miRNA signature in bladder cancer, reporting an association between a high 
expression of Let-7c-5p and a poor outcome43. At a similar extent, high levels of miR-151 correlated with adverse 
effects on survival rate in prostate cancer44. Interestingly, both these miRNAs were reported to be associated with 
dysregulated metabolic conditions. In fact, Let-7c-5p plays a protective role against cerebral ischemia injury in 
mice45, while miR-151a-5p regulates energy metabolism reducing ATP production via mitochondrial dysfunc-
tion46. We have already stressed the role of mitochondrial abnormalities in MPM47, and we believe that hypoxia 
plays a crucial role in the resistance of MPM to conventional therapies. Let-7c-5p is reported to be involved 
in regulation of hypoxia48, 49, and can be considered members of the so-called “HypoxamiRs”, a group of miRs 
modulated by hypoxic conditions, involved in EMT and chemo-resistance and associated with worse prognosis50. 
Other evidences showed how miR-151-5p overexpression is linked with energy metabolism derangement and 
suggested a link with hypoxia51. This could explain their association with the overall survival that we observed 
here, since their high expression could promote the hypoxic microenvironment very well known to activate many 
signalling pathways involved in tumour initiation, progression and maintenance of MPM52, 53.
Although we provided overall reliable data about miRNA dysregulation in MPM, there are some limitations 
to the present study. First, we acknowledge a partial lack of clinical information for several patients since the 
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sample collection was performed in different hospitals with different capabilities in retrieving old information 
from their records. Thus, the inclusion of more and more complete demographic details in the analyses for the 
identification of miRNA with diagnostic value could have improved the quality of the data provided. This limita-
tion is particularly relevant in the prognostic calculations for the 2-microRNA signature, which were then done 
on relatively small sample numbers (n = 52, and information about relevant treatment was available only for 27 of 
them). Regarding the role of therapeutic treatments as prognostic variable, we acknowledge that our analysis was 
unable to discriminate among different treatments, since we simply grouped individuals in non-symptomatic vs 
symptomatic therapy in order to allow a sufficient statistical power in the multivariate analysis.
Despite this partial lack of clinical information, the baseline demographic features (age, gender and histologi-
cal subtype) did not show any statistically significant difference between the cohorts with versus without survival 
data (see Supplementary Table 5 for further details), suggesting that the 2-miRNA prognostic signature could be 
applied to our entire sample set. Moreover, as explained in Table 4 and below in the materials and methods sec-
tion, sufficient RNA could not be isolated from all samples, reducing the number of samples available for analysis. 
However, comparison of baseline characteristics of patients with and without RNA showed that there were no 
major differences between the respective groups (see Supplementary Table 5 for further details), thus the samples 
that we actually analysed were representative of a more general population.
Conclusion
In conclusion, with the present work we showed that the pattern of miRNAs expression is highly deregulated 
in MPM, as reported in many other tumour types. We also suggest that alterations in miRNA expression could 
modify cell pathways regulation and could allow the discovery of new druggable targets, following appropriate 
experimental validation. We also identified a 2-miRNA signature as useful biomarker for prognosis in MPM 
clearly addressing toward a role of metabolism in MPM aggressiveness. Patients stratified in high risk group, by 
our classifier, might benefit either of more targeted and aggressive cures or therapies targeting metabolic repro-
gramming in order to improve their outcome. Further studies on the miRNA target-genes are needed to better 
ascertain their fruitful exploitation as therapeutic targets or as diagnostic and prognostic biomarkers of MPM.
Materials and Methods
For this work, according to the Helsinki declaration, volunteers gave informed consent for the research. The study 
was approved by the institutional ethical committee of the University Hospital of Pisa. All the experimental pro-
tocols were carried out according to the relevant guidelines, as explained in details in the sections below.
Tissue collection. A consecutive series of 105 MPM patients provided corresponding 105 formalin-fixed 
paraffin-embedded MPM tissues. The MPM FFPE samples were biopsies collected from 2005 to 2009 in collabo-
ration with the units of Thoracic Surgery and Occupational Medicine at the University Hospital of Pisa, together 
with the Hospital of Brescia, the Hospital of Venice (ASL 12), and the IRCCS AOU San Martino-IST in Genoa. 
All institutions providing the tissues followed the same protocol of sample collection and tissue preparation. The 
Variables
Tot MPM Cohort (n = 105) Tot non-MPM Cohort (n = 10)
Patients with RNA (n = 96) Patients without RNA (n = 9) Patients RNA (n = 10)
Patients with demographic information 
(n = 66)&
Patients with demographic 
information (n = 7)&
Patients with demographic 
information (n = 10)
With survival data 
(n = 52)
Without survival 
data (n = 14)*
With survival 
data (n = 7)
Without survival 
data (n = 0)
Mean age (range) 65.5 (41–85) 69 (68–70) 72.8 (67–80) N/A 72.4 (57–84)
Gender
Male 35 (67%) 2 (100%) 5 (71%) N/A 7 (70%)
Female 17 (33%) 0 (0%) 2 (29%) N/A 3 (30%)
Histological subtype
Epithelioid 43 (83%) 14 (100%) 4 (57%) N/A
Biphasic 8 (15%) 0 (0%) 3 (43%) N/A
Sarcomatoid 1 (2%) 0 (0%) 0 (0%) N/A
Median OS (months) 
(range) 11.5 (1–70) N/A 12 (8–22) N/A
Therapy$
Non-symptomatic£ 13
Symptomatic 14
Table 4. Demographic characteristic of the FFPE samples collected for the microarray study (n = 105 
MPM and n = 10 normal pleural tissue). &Total number of MPM patients with partial/total demographic 
information is 73 (66 + 7); *For this group the information about gender and age was available only for 2/14 
patients; N/A = not available; $Data was available only on 27/105 samples, all falling within the patients 
group with survival data; £Non-symptomatic therapy included pleurectomy with decortication (P/D) (n = 3), 
P/D + chemotherapy (n = 3), pleuropneumonectomy (n = 1), pleuropneumonectomy + chemotherapy (n = 3), 
pleuropneumonectomy + chemotherapy + radiotherapy (n = 2), pleuropneumonectomy + radiotherapy (n = 1).
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MPM diagnosis was issued from pathologists, following the standard clinical routine that was based on micro-
scopic inspection and immuno-histochemical analyses of slides with antibodies to detect a panel of biomarkers 
(CK5/6, calretinin, vimentin, CK-Pan, EMA, TTF1, BerEP4, CEA). Pleural tissue specimens for the control sam-
ple set (n = 10) were collected in the University Hospital of Novara from individuals with chronic pleuritis (n = 6) 
and mesothelial hyperplasia (n = 4). Samples were selected for the microarray study only when RNA of sufficient 
quality and quantity was available after extraction from FFPE tissues. Nine MPM FFPE samples among the 105 
available did not meet the quality criteria either in the RNA extraction or in the microarray run. Baseline charac-
teristics of the 105 MPM patients (including the 96 samples used in the study) and the 10 non-MPM individuals 
are provided in Table 4. We used the full cohort of 96 RNA samples with known diagnosis of MPM to identify 
miRNAs with a potential diagnostic value, i.e. miRNAs that were differentially expressed between MPM and nor-
mal pleural samples. Among the 96 MPM patients used in this study, partial/total demographic information was 
available for 66 individuals. The survival time, calculated from the date of diagnosis, was available for 52 patients, 
who were then also employed to identify miRNAs with a potential prognostic value.
For the validation analysis, 22 MPM biopsies were collected during thoracoscopy in collaboration with the 
units of Thoracic Surgery and Occupational Medicine at the University Hospital of Pisa (Italy) before any treat-
ment. About 70% of MPM patients had an ascertained positive history of exposure to asbestos, and approximately 
half of them had also a positive cigarette smoking history. Control tissues (20) were normal pleura from patients 
who underwent surgery for early-stage lung cancer (6 lung adenocarcinomas and 14 lung squamous cell car-
cinomas). Pleural specimens were collected far from the tumour site, eye-inspected by surgeons and analysed 
by pathologists in order to collect a small portion of pleura not containing evidence of lung cancer spread. All 
samples were fresh frozen, stored in the RNA later reagent (Qiagen, Hilden, Germany) and placed at −80 °C right 
after the collection. Following the same criteria of the microarray study, samples were selected for the validation 
study only when RNA of sufficient quality and quantity was available after extraction from fresh frozen tissues, 
and for this reason six and three RNA samples were excluded among the MPM and non-MPM subgroup, respec-
tively. Baseline characteristics of the 42 MPM and non-MPM samples and the subset of 33 patients used in this 
validation study are provided in Table 5. The validation of the 2-miRNA signature was performed on the full set 
of 16 MPM with RNAs as the survival time was available for all of them.
Microarray Study. RNA extraction. Total RNAs were isolated from formalin-fixed paraffin-embedded tis-
sues (FFPE) using Recover All kit (Thermo Fisher Scientific, Waltham, USA), following manufacturer’s protocol. 
About 100 ng of total RNA per samples was then processed with the Human miRNA Expression Assay from 
NanoString nCounter system (nanoString, Seattle, Washington, USA).
nanoString nCounter profile analysis. RNAs were processed by the nanoString nCounter system (nanoString, 
Seattle, Washington, USA) in the Nucleic Acid Shared Resource of The Ohio State University. The miRNA panel 
detects 800 endogenous miRNAs, five housekeeping transcripts [actin beta (NM_001101.2), beta-2 microglobu-
lin (NM_004048.2), GAPDH (NM_002046.3), RPL19 (NM_000981.3), and RPLP0 (NM_001002.3)], six positive 
and eight negative controls (proprietary spike-in controls).
Data analysis, statistical methods, and figures. Raw expression data, which are proportional to copy number, 
were log-transformed and normalized by the quantile method after application of a manufacturer-supplied cor-
rection factor. Data were filtered to exclude features below the detection threshold (defined for each sample by a 
cutoff corresponding to ~twice standard deviation of negative control probes plus the means) in at least half of the 
samples. Using R/Bioconductor and the filtered dataset, linear models for microarray data analysis (limma) were 
employed with a contrast matrix for comparing normal vs tumour. Raw data that were above background (analy-
sis not shown), as well as the corresponding quantile-normalized data, were also imported into MultiExperiment 
Viewer. Data processing and analysis were conducted using BRB-ArrayTools54, the MultiExperiment Viewer55, 
and R/BioConductor packages including limma56. The analysis of raw data was performed with nSlover Analysis 
Software provided by NanoString Technologies®. Data were collected as NanoString RCC files and provided as an 
Variables
Tot MPM Cohort (n = 22) Tot non-MPM cohort (n = 20)
Patients with 
RNA (n = 16)
Patients without 
RNA (n = 6)
Patients with 
RNA (n = 17)
Patients without 
RNA (n = 3)
Mean age (range)* 63.3 (40–77) 77 (64–87) 73.5 (59–85) 67.6 (63–72)
Gender
Male 13 (81%) 5 (83%) 10 (59%) 2 (67%)
Female 3 (19%) 1 (17%) 7 (41%) 1 (33%)
Histological subtype
Epithelioid 11 (69%) 4 (66%)
Biphasic 4 (25%) 0 (0%)
Sarcomatoid 1 (6%) 2 (33%)
Median OS (months) (range) 19.5 (6–53) 14.5 (1–41)
Table 5. Demographic characteristic of the fresh frozen samples collected for the validation study (n = 22 MPM 
and n = 20 normal pleural tissue). *Statistically different between patients with RNA and patients without RNA 
in the MPM subgroup (defined as p < 0.05 in Student’s t-test).
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Excel spreadsheet. P values were used to rank miRNAs of interest, and correction for multiple comparisons was 
done by the Benjamini-Hochberg (BH) method57.
Survival analysis was carried out using Kaplan–Meier curves on 52 MPM patients. To generate a risk score, we 
adopted a previously developed strategy58 that uses the Cox proportional hazards regression analysis to identify 
the miRNA associated with survival. MiRNAs whose expression was statistically significantly associated with 
survival at P ≤ 0.05 were selected by fitting Cox proportional hazards models to each miRNA in the training data. 
A Cox proportional hazards model was built using the principal components calculated from the statistically 
significant miRNA list. The OS and a risk score for each patient was calculated by multiplying the expression 
level of the 2 miRNAs by their corresponding Cox regression coefficient and summing the resulting values (risk 
score = sum of each Cox coefficient of miRNA x expression value of the corresponding miRNA). Thus, patients 
were dichotomized into groups at high or low risk using the 50th percentile (median) cutoff of the risk score as 
the threshold value. In order to validate our prognostic signature, the TCGA mesothelioma dataset (validation 
set/cohort, http://cancergenome.nih.gov/cancersselected/Mesothelioma) was used an independent set. MiRNA 
expression data for 83 tumours from patients with MPM were downloaded and the survival analysis was carried 
out applying directly the Cox coefficient derived by our cohort.
The performances of the 2-microRNA signature and single microRNAs for OS were compared by AIC, a 
measure of global fit that offers a relative estimate of the information lost when a given model is used to represent 
the process that generates the data, where low AIC values indicate better fit59.
The effect of other known prognostic factors on the survival of 52 MPM patients (histological subtype, 
gender and age) was also tested together with the risk score in a multivariate Cox proportional hazard model. 
Moreover, information about therapy was available for 27 patients with survival data, thus we performed another 
multivariate analysis considering the 2-miRNA risk score and the treatment (symptomatic therapy, n = 13, vs 
non-symptomatic therapy, n = 14) as prognostic variables.
Validation study. RNA isolation and cDNA synthesis. RNA from individual biopsies was purified by using 
Tri-Reagent method (Sigma Aldrich Corp. St Louis, MO, USA). In order to remove any contaminating genomic 
DNA, the extracted RNA was treated with DNase (Sigma Aldrich Corp. St Louis, MO, USA) and its concentra-
tion was determined by spectrophotometer (SmartSpec 3000, Bio-Rad Laboratories, Hercules, CA). The integrity 
and purity of total RNA were further verified by electrophoresis on ethidium bromide agarose gel, inspecting the 
18 and 28 S ribosomal RNA bands. RNAs which did not meet the quality criteria (i.e. good concentration and 
integrity) were excluded from the analyses. The reverse transcription (RT) was performed using the TaqMan® 
MicroRNA Reverse Transcription Kit (Life Technologies, Monza, Italy) using stem-loop specific miRNA primers 
starting from 100 ng of total RNA.
Selection of reference miRNAs for RT-qPCR and RT-qPCR. In order to perform accurate RT-qPCR measure-
ments, we tested a panel of possible reference miRNAs/short RNAs commonly used in miRNA expression anal-
yses. The stability of each of them was measured by geNorm60 and, according to the average M and the pair-wise 
variation values, U6, RNU48, RNU44 were found stable and were employed as reference miRNAs in all the exper-
iments. Pre-designed TaqMan probes (Life Technologies, Monza, Italy) were employed. For the TaqMan assay, the 
reaction mixture consisted of 1.33 μl of cDNA template, 7.67 μl of deionized H2O, 1 μl of specific TaqMan Assay 
probe and primer mixture, and 10 μl of TaqMan® Universal Master Mix II NO UNG (Life Technologies, Monza, 
Italy). The thermal cycling conditions were: 10 min at 95 °C followed by 40 cycles made of 15 s at 95 °C and 60 s at 
60 °C. TaqMan ID assays are reported in Supplementary Table 5. Each sample was run in triplicate, and the quality 
control of the derived expression values was performed according to MIQE guidelines61.
Statistical analyses. For validation analysis, miRNAs expression levels from MPM samples were compared to 
control tissue samples by applying the two-sided Mann–Whitney–Wilcoxon test. The adjustment for multiple 
testing was performed by using Bonferroni’s correction, thus the novel statistical significance threshold was 0.01. 
Data analysis was produced by the software Statgraphics Centurion XV (StatPoint, Inc.). Moreover, in order to 
confirm the 2-miRNA signature associated with prognosis, the OS and a risk score for each patient was calculated 
as previously explained for the microarray set of analyses.
In silico analyses. In silico prediction of the potential target mRNAs was performed for each interesting 
miRNA using DIANA-microT-CDS tool62, with threshold set at 0.6. DIANA-miRPath63 was employed to perform 
the over-representation analysis using the differentially expressed miRNAs as input list. DIANA-miRPath allows 
the identification of miRNA-target genes, either predicted (the “microT-CDS” mode) or experimentally validated 
(the “TarBase” mode). The option “Union Set”, that collects all genes targeted by at least one selected miRNAs, was 
applied for the over-representation analysis.
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